Pregledni rad

The side effects of new oral anticoagulants

Alma Starčević ; Klinički zavod za transfuzijsku medicinu, KBC Rijeka, Rijeka
Nada Vukelić-Damijani ; Klinički zavod za transfuzijsku medicinu, KBC Rijeka, Rijeka
Sanja Balen ; Klinički zavod za transfuzijsku medicinu, KBC Rijeka, Rijeka
Vera Vlahović-Palčevski ; Odjel za kliničku farmakologiju, KBC Rijeka, Rijeka

Sažetak

New oral anticoagulants (NOACs), direct thrombin inhibitor (dabigatran etexilat) and factor Xa inhibitors (rivaroxaban and apixaban) both show noninferiority or even superiority to warfarin in the prevention or treatment of venous thromboembolism. This brief review describes the mechanism of action, clinical use and side effects of new oral anticoagulants. Like all other anticoagulant drugs, the NOACs carry an increased risk of bleeding. Unlike warfarin, the NOACs represent a clinical challenge due to the lack of specific antidotes and tests for the measurement of drug levels. When choosing anticoagulant therapy, the
physician must apply a personalized approach to each patient.

Ključne riječi

apixaban; dabigatran etexilat; rivaroxaban; side effects

Hrčak ID:

139472

URI

https://hrcak.srce.hr/139472

Datum izdavanja:

1.6.2015.

Podaci na drugim jezicima: hrvatski

Posjeta: 7.448 *